First immunotherapy for advanced basal cell carcinoma approved in US
In trials Libtayo® caused clinically meaningful and durable responses, resulting…
In trials Libtayo® caused clinically meaningful and durable responses, resulting in the drug being fully approved for advanced basal cell carcinoma resistant to other treatments.